Sysmex Co. (OTCMKTS:SSMXY) Sees Large Decline in Short Interest

Sysmex Co. (OTCMKTS:SSMXY) was the target of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 2,400 shares, a decline of 63.1% from the March 31st total of 6,500 shares. Based on an average daily volume of 90,400 shares, the days-to-cover ratio is currently 0.0 days.

Sysmex Stock Down 1.6 %

OTCMKTS SSMXY traded down $0.26 on Friday, hitting $15.85. The stock had a trading volume of 76,508 shares, compared to its average volume of 56,791. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.10 and a quick ratio of 2.27. The stock has a market cap of $9.98 billion, a price-to-earnings ratio of 31.79 and a beta of 0.66. Sysmex has a 52-week low of $15.02 and a 52-week high of $36.57. The business’s fifty day moving average price is $17.44 and its 200 day moving average price is $17.51.

Sysmex (OTCMKTS:SSMXY) last issued its quarterly earnings results on Friday, February 9th. The company reported $0.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.03). Sysmex had a return on equity of 11.15% and a net margin of 10.25%. The firm had revenue of $770.84 million for the quarter. Equities research analysts anticipate that Sysmex will post 0.53 earnings per share for the current year.

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.